Bakker Juliet Tammenoms
CIK 1431159 · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.28B
Companies
15
Total Filings
52
Lifetime Open-Market Net
$193.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CBLL | Director | 2,498,394 | $18.47 | $46.15M | $4.03M | 3 | 2026-06-04 |
| RXST | Director | 49,694 | $4.71 | $234.1K | -$13.82M | 17 | 2025-06-04 |
| VERA | 10%+ Owner | 3,429,927 | $34.26 | $117.51M | $60.00M | 1 | 2023-02-08 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 175,000 | $54.99 | $9.62M | $28.35M | 3 | 2022-02-02 |
| RPID | 10%+ Owner | 150,000 | $1.76 | $264.0K | $18.00M | 1 | 2021-07-20 |
| Eargo, Inc. (EAR) Delisted | Director | 1,925,707 | $2.57 | $4.95M | $4.20M | 4 | 2021-05-19 |
| Tourmaline Bio, Inc. (TALS) Delisted | 10%+ Owner | 3,220,775 | $27.20 | $87.61M | $15.98M | 1 | 2021-05-11 |
| Axonics, Inc. (AXNX) Delisted | Director | 1,958,833 | $70.98 | $139.04M | $7.51M | 9 | 2020-09-22 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $29.85M | 2 | 2020-09-01 |
| Venus Concept Inc. (HAIR) Delisted | Director | 3,476,584 | — | — | $0 | 1 | 2019-11-07 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 3,019,734 | $0.11 | $326.1K | $10.00M | 1 | 2018-07-02 |
| Aptinyx Inc. (APTX) Delisted | 10%+ Owner | 3,190,079 | $0.06 | $194.6K | $7.20M | 1 | 2018-06-26 |
| COLL | 10%+ Owner | 6,029,785 | $34.64 | $208.87M | $12.30M | 2 | 2018-02-26 |
| CORT | Director | 10,874,259 | $82.91 | $901.58M | $11.70M | 4 | 2016-12-19 |
| ESPR | 10%+ Owner | 1,883,769 | $3.15 | $5.93M | -$1.55M | 2 | 2014-10-14 |
Recent Filings · Page 2 of 6
52 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-28 | RXST | Mixed | −282,122 | -$474.1K | EDGAR |
| 2023-08-18 | RXST | Sell (S) | −33,135 | -$981.6K | EDGAR |
| 2023-08-11 | RXST | Other (J) | −464,200 | $0 | EDGAR |
| 2023-06-16 | RXST | Other (J) | −265,839 | $0 | EDGAR |
| 2023-06-05 | RXST | Grant (A) | +5,731 | $0 | EDGAR |
| 2023-05-31 | RXST | Other (J) | −464,015 | $0 | EDGAR |
| 2023-02-13 | RXST | Buy (P) | +480,000 | $6.00M | EDGAR |
| 2023-02-08 | VERA | Buy (P) | +8,571,425 | $60.00M | EDGAR |
| 2022-06-03 | RXST | Grant (A) | +10,349 | $0 | EDGAR |
| 2022-02-02 | Sierra Oncology, Inc. (SRRA) Delisted | Buy (P) | +1,050,000 | $28.35M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.